Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | OSBP | P22059 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849326 | 1.00 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL24141990 | 1.00 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL837968 | 0.97 | POLA1 (0.43) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL15186906 | 0.96 | POLA1 (0.45) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL19272838 | 0.96 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL4546173 | 0.96 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL14652823 | 0.96 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL13556705 | 0.96 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL19152812 | 0.96 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP | |
| SCHEMBL15959349 | 0.95 | POLA1 (0.48) | POLA1PLA2G2ACYP46A1NR1H3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257740-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| EP-3208337-A1 | COMPOSITIONS FOR COMBINED INHIBITION OF MUTANT EGFR AND IL-6 EXPRESSION | Alnylam Pharmaceuticals, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2552456-B1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160090593-A1 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR) | ALNYLAM PHARMACEUTICALS, INC. | 2016-03-31 | — | — | US | disclosed |
| EP-2331690-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9234196-B2 | Compositions and methods for inhibiting expression of transthyretin | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9101643-B2 | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9062310-B2 | Compositions and methods for inhibiting expression of factor VII gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2810643-A2 | Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus | Alnylam Pharmaceuticals Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140343122-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-7320965-B2 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | ALNYLAM PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | ALNYLAM PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281899-A1 | double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene | GEMIN5, RNASE1, EFTUD2 | POLA1 272/4885PLA2G2A 865/4885CYP46A1 3434/4885 |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | RHOA, RHOC, ARHGDIA | POLA1 2346/4885PLA2G2A 423/4885CYP46A1 1413/4885 |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | HTT, HYPK, DHX36 | POLA1 256/4885PLA2G2A 2595/4885CYP46A1 4172/4885 |
| US-20230257740-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | POLA1 662/4885PLA2G2A 2597/4885CYP46A1 847/4885 |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | RHOA, ARHGDIA, RHOC | POLA1 2746/4885PLA2G2A 407/4885CYP46A1 1564/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | POLA1 1142/4885PLA2G2A 905/4885CYP46A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.